Shots:
- The P-III (OCEANIC-STROKE) trial assessed asundexian (50mg, QD, PO) vs PBO, both in combination with antiplatelet therapy, in pts (n=12,327) for prevention of ischemic stroke after a non-cardioembolic ischemic stroke or high-risk transient ischemic attack
- Trial showed a 26% reduction in recurrent ischemic stroke without increased ISTH major bleeding across all subgroups, met key 2EPs incl. a 26% reduction in any stroke risk (ischemic & hemorrhagic)
- The trial also achieved composite EPs of CV death, MI or stroke, & all-cause death, MI or stroke; data to be presented at the International Stroke Conference 2026
Ref: Bayer | Image: Bayer | Press Release
Related News: Genethon Signs Worldwide Licensing Agreement with AskBio (Bayer AG) to Advance Gene Therapy for Pompe Disease
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
